ASCO: Biologic Agents Plus Chemo Equal in Colon Ca
CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical trial.
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Erbitux | General Medicine